PedsQL Cancer Module
Also known as: PedsQL 3.0 Cancer
The PedsQL Cancer Module is a 31-item disease-specific instrument developed by Varni et al. in 2002 to measure quality of life in children and adolescents with cancer aged 2–18 years. It captures treatment burden (nausea, vomiting, pain, hair loss), cancer-related worry, cognitive concerns, and emotional and social impacts of diagnosis and treatment. Used alongside the PedsQL Generic Core Scales, it provides comprehensive assessment of both cancer-specific and general health-related quality of life during active treatment, survivorship, and end-of-life care.
Key highlights
- Comprehensive disease-specific assessment captures cancer-unique impacts (chemotherapy side effects, cancer worry, uncertainty about the future) that generic measures cannot.
- Multi-domain structure identifies specific areas of cancer burden (e.g., separating pain, nausea, and fatigue) to guide targeted interventions.
- Parallel child and parent versions enable assessment of child experience and parental perception; discrepancies are often clinically informative.
- Integrates with PedsQL Generic Core Scales for comprehensive QoL measurement spanning both disease-specific and general functioning.
- Responsive to changes in cancer stage, treatment intensity, and transition to survivorship or end-of-life care.
- Validated across pediatric cancer types (leukemia, solid tumors, lymphoma) and ages 2–18 years.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
The PedsQL Cancer Module is indicated for children and adolescents aged 2–18 years with any cancer diagnosis during active treatment, survivorship, or palliative care. It is particularly valuable in oncology clinical trials evaluating new chemotherapy regimens or supportive care interventions, in longitudinal quality-of-life monitoring in pediatric cancer clinics, in assessment of psychosocial outcomes alongside medical endpoints, and in palliative and end-of-life care planning. The instrument is not appropriate for children without cancer or for adult cancer populations (which have different developmental concerns and treatment sequelae).
Strengths & limitations
- Comprehensive disease-specific assessment captures cancer-unique impacts (chemotherapy side effects, cancer worry, uncertainty about the future) that generic measures cannot.
- Multi-domain structure identifies specific areas of cancer burden (e.g., separating pain, nausea, and fatigue) to guide targeted interventions.
- Parallel child and parent versions enable assessment of child experience and parental perception; discrepancies are often clinically informative.
- Integrates with PedsQL Generic Core Scales for comprehensive QoL measurement spanning both disease-specific and general functioning.
- Responsive to changes in cancer stage, treatment intensity, and transition to survivorship or end-of-life care.
- Validated across pediatric cancer types (leukemia, solid tumors, lymphoma) and ages 2–18 years.
- No published MCID; clinically meaningful change thresholds must be estimated from other instruments or expert consensus.
- Requires administration of both Cancer Module and Generic Core Scales for comprehensive assessment; total administration time is 15–20 minutes, which may be burdensome in high-volume clinics.
- Parent-child discrepancies are common (particularly in adolescents); interpretation can be ambiguous when perspectives diverge significantly.
- Baseline assessment during active treatment is often emotionally challenging for families; timing of assessment must be sensitive to clinical circumstances.
- Limited normative data; interpretation relies on baseline-to-follow-up comparison or group means rather than population reference values.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Should I use the PedsQL Cancer Module alone or with the Generic Core Scales?
Use both. The Cancer Module captures disease-specific impacts (pain, nausea, cancer worry), while the Generic Core Scales measure general health-related quality of life (physical, emotional, social, school functioning). Together, they provide a full picture. Using only the module may miss important impacts on general functioning not directly attributable to cancer.
What is a clinically meaningful change on the PedsQL Cancer Module?
There is no published MCID specific to the Cancer Module. Based on other PedsQL modules and clinical judgment, improvements of 5–10 points per scale are often considered meaningful. In practice, changes should be contextualized to the child's clinical situation (e.g., a 5-point fatigue improvement after completing chemotherapy is very meaningful; the same change in a child stable on maintenance therapy may reflect measurement variability).
Can I use the Cancer Module for children with other serious illnesses (e.g., cystic fibrosis, diabetes)?
No. The Cancer Module is specifically validated for pediatric cancer. Children with other chronic conditions require disease-specific measures (e.g., Cystic Fibrosis Questionnaire, PedsQL Diabetes Module). Using the Cancer Module in non-cancer populations will yield data that cannot be meaningfully interpreted.
What age range is the PedsQL Cancer Module validated for?
Child self-report is validated for ages 5–18 years. Parent proxy is available for ages 2–18 years. For very young children (age 2–4), parent proxy is the only option. For adolescents (13–18), self-report is strongly preferred, though parent perspective is also valuable.
Sources
- 1.Varni, J. W., Burwinkle, T. M., Katz, E. R., Meeske, K., & Dickinson, R. P. (2002). The PedsQL in pediatric cancer: Reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, multidimensional fatigue scale, and cancer module. Cancer, 94(7), 2090-2106.
- 2.Varni, J. W., Seid, M., & Rode, C. A. (2000). The PedsQL: Measurement model for the Pediatric Quality of Life Inventory. Medical Care, 37(2), 126-139.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). PedsQL Cancer Module. ScholarGate. https://scholargate.app/pediatric-medicine/pedsql-cancer